Kevin Freeman-Cook, PhD, our VP of Chemistry, will present in the first disclosure session at the upcoming American Chemical Society (ACS) Fall Meeting, focusing on the discovery of PLX-4545, a molecular glue degrader of IKZF2. The meeting will take place in Denver, CO, and virtually, on August 18-22, 2024. Learn more here: https://lnkd.in/eZbQiH5j #biotech #drugdiscovery #drugdesign #pharma #ACSfall2024
Plexium
Biotechnology Research
San Diego, California 5,111 followers
Pushing the Boundaries of Targeted Protein Degradation to Improve Lives
About us
Plexium is the premier, next-generation targeted protein degradation company, seeking to discover a wide range of monovalent target protein degraders that address the limitations of PROTACs and cereblon. The company’s platform is a proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases.
- Website
-
http://www.plexium.com
External link for Plexium
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
11494 Sorrento Valley Rd
San Diego, California 92121, US
Employees at Plexium
Updates
-
We are pleased to share that Kevin Freeman-Cook, PhD, our VP of Chemistry, is presenting at the Medicinal Chemistry GRC Conference. The meeting will take place from August 11 to 16 in New London, NH. More information can be found here: https://lnkd.in/eunNmF9q #biotech #drugdiscovery #drugdesign #pharma #GRC2024
-
-
We are thrilled to welcome Serge Messerlian of DCVC to the Plexium board of directors! Serge brings over 25 years of biotech experience to our board, with a proven track record in company building, executive leadership in R&D and large pharma companies, strategic planning and fundraising. https://lnkd.in/gE-_An6b
-
-
Next week, our Chief Financial Officer, Stephen Mullennix, is scheduled to present at the Oppenheimer & Co. Inc. 34th Healthcare Conference virtually on Tuesday, February 13th, at 12 pm ET. Plexium management will also participate in one-on-one meetings with investors during the conference. #OPCOLifeScience #biopharma #TPD #proteindegradation
-
2024 is off to a great start at Plexium. We recently initiated the PLX-4545 Phase 1 study; we continue to advance our preclinical pipeline of monovalent degraders of SMARCA2, CDK2 and c-Raf; and today, we announced the appointment of Michael Martin, Ph.D. as President and CEO. Read our full press release to learn more about Plexium and our mission: https://lnkd.in/gxUcSg2B #tpd #drugdiscovery #pharma #biotech
Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO
prnewswire.com
-
We are thrilled to announce the appointment of Michael Martin, Ph.D. as our new President and CEO. Michael is a seasoned scientific executive and global R&D leader, who joins us following a 12-year tenure at Takeda Pharmaceuticals. His expertise in research & development activities, business development, and venture investment positions him perfectly to lead Plexium into a new era of growth. Learn more about this exciting news here: https://lnkd.in/gxUcSg2B #tpd #drugdiscovery #pharma #biotech
Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO
prnewswire.com
-
Plexium is pleased to announce that the first subjects have been dosed in a Phase 1 study of PLX-4545, a potent and selective molecular glue degrader of IKZF2, a classically undruggable transcription factor. Initiation of this study represents an important milestone for Plexium, as PLX-4545 is our first small molecule degrader program stemming from our proprietary drug discovery platform to enter human studies. Learn more here: https://bit.ly/3Nnsfr2 #tpd #drugdiscovery #drugdesign #pharma #biotech
-
-
Last week, our Plexium team joined forces for a volunteer day at the Jacobs & Cushman San Diego Food Bank. Together with other group, we packed an incredible 10,221 pounds of fruit, destined to make a difference in the lives of families in need. And after our meaningful work, we gathered for a heartwarming Thanksgiving feast! #graditude #makingadifference
Plexium, Making a Difference!
https://www.plexium.com
-
Today, Stephen Mullennix, our Chief Financial Officer, is attending the Bank of America Healthcare Trailblazers Private Company Conference and will be participating in one-on-one meetings with investors during the conference. #biopharma #TPD #proteindegradation #science
Plexium Attending the Bank of America Healthcare Trailblazers Private Company Conference
https://www.plexium.com
-
At our recent Science Day, Plexium’s talented scientists and technologists shared examples of their innovative work with colleagues from across the company. A highlight of Science Day was a poster session featuring 21 posters demonstrating Plexium's advancements in chemistry, biology, screening, proteomics, and technology. Collaboration and shared learning are integral to our scientific culture at Plexium, and we were thrilled by the engagement of our colleagues across the entire company. Learn more about Plexium here. https://www.plexium.com/ #tpd #proteindegradation #drugdiscovery #drugdesign #pharma #biotech #discoveryontarget #sandiegobiotech #scienceday
Science Day at Plexium!
https://www.plexium.com